胃腺癌（GCPM）引起的腹膜转移预后不佳。一种有前途的治疗策略是细胞减灭术和腹腔热灌注化疗（CRS-HIPEC），但缺乏明确的 GCPM 资格标准。我们试图确定与 GCPM CRS-HIPEC 后总生存 (OS) 相关的因素，以帮助优化患者选择和临床结果。在这项单中心回顾性队列研究中，我们检查了 2001 年至 2021 年间 GCPM 患者的 CRS-HIPEC 结果在分析患者人口统计学、临床病理学和围手术期变量后，我们应用多变量 Cox 风险模型来评估与 OS 相关的因素。然后，我们使用多变量逻辑回归评估了基线预测因子和重要预后变量之间的关联。我们分析了 55 名接受 CRS-HIPEC 的 GCPM 患者。中位年龄为 54 岁，其中 42% 为女性。中位腹膜癌病指数 (PCI) 为 8，75% 的患者细胞减灭完整性评分 (CC 评分) 为 0。中位无进展生存期 (PFS) 为 6.9 个月，中位 OS 为 14.1 个月。根据调整后的分析，CC 评分 > 0（HR 2.3，p = 0.02）与较差的 OS 显着相关。在异时环境中，腹膜癌变指数大于 13（OR 52.6，p = 0.001）和与原发肿瘤一起切除的淋巴结较少（特别是 < 18）（OR 0.86，p = 0.042）与不完全肉眼肿瘤细胞减灭术 (CC) 显着相关。评分 > 0）。我们证明，异时性肿瘤中 PCI > 13 和原发淋巴结采集 < 18 与 CC 评分 > 0 相关，这反过来预示着更差的 OS。尽管这些结果值得前瞻性验证，但它们为改进 GCPM 患者 CRS-HIPEC 的选择提供了见解。© 2024。外科肿瘤学会。

Peritoneal metastases due to gastric adenocarcinoma (GCPM) carry a dismal prognosis. A promising treatment strategy is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), but clear eligibility criteria for GCPM are lacking. We sought to identify factors associated with overall survival (OS) following CRS-HIPEC for GCPM to help optimize patient selection and clinical outcomes.In this single-center retrospective cohort study, we examined CRS-HIPEC outcomes for patients with GCPM between 2001 and 2021. After analyzing patient demographic, clinicopathologic, and perioperative variables, we applied multivariable Cox hazard models to assess factors associated with OS. We then assessed associations between baseline predictors and prognostically important variables using multivariable logistic regression.We analyzed 55 patients with GCPM who underwent CRS-HIPEC. Median age was 54 years and 42% were female. Median peritoneal carcinomatosis index (PCI) was 8, and 75% of patients achieved a cytoreduction completeness score (CC score) of 0. Median progression-free survival (PFS) was 6.9 months, and median OS was 14.1 months. On adjusted analysis, a CC score > 0 (HR 2.3, p = 0.02) was significantly associated with worse OS. A peritoneal carcinomatosis index greater than 13 (OR 52.6, p = 0.001) and fewer lymph nodes (especially < 18) resected with the primary tumor (OR 0.86, p = 0.042) in the metachronous setting were significantly associated with incomplete macroscopic cytoreduction (CC score > 0).We demonstrated that PCI > 13 and primary lymph nodes harvested < 18 in metachronous tumors are associated with CC score > 0, which in turn portends a worse OS. Although these results warrant prospective validation, they provide insight into improved selection of patients with GCPM for CRS-HIPEC.© 2024. Society of Surgical Oncology.